Barely Significant
← all excerpts

Nucleotide-Binding Oligomerization Domain 1/Toll-Like Receptor 4 Co-Engagement Promotes Non-Specific Immune Response Against K562 Cancer Cells.

Front Pharmacol · 2022 · PMC9354050 · PMID 35935855

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

extremely significantp < 0.001actually significant
highly significantp < 0.01actually significant
Differences were considered significant (*) for p < 0.05, highly significant (**) for p < 0.01, and extremely significant (***) for p < 0.001.

also in 7,074 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.